Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1969 2
1970 2
1971 2
1972 3
1973 2
1975 2
1976 1
1977 2
1978 1
1979 1
1980 4
1981 1
1982 3
1983 4
1984 1
1985 1
1986 1
1987 3
1989 1
1990 5
1991 4
1992 1
1993 1
1994 4
1995 4
1996 3
1997 5
1998 6
1999 2
2000 2
2001 3
2002 7
2003 1
2004 8
2005 5
2006 3
2007 14
2008 8
2009 12
2010 7
2011 13
2012 13
2013 14
2014 11
2015 14
2016 21
2017 14
2018 19
2019 18
2020 12
Text availability
Article attribute
Article type
Publication date

Search Results

267 results
Results by year
Filters applied: . Clear all
Page 1
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Kappos L, et al. Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Lancet. 2018. PMID: 29576505 Clinical Trial.
BACKGROUND: No treatment has consistently shown efficacy in slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS). ...METHODS: This event-driven and exposure-driven, double-blind, phase 3 trial was done at 292 hospita …
BACKGROUND: No treatment has consistently shown efficacy in slowing disability progression in patients with secondary progressive multipl
[Indications for varicella zoster and herpes zoster vaccination in multiple sclerosis: current situation].
Winkelmann A, Löbermann M, Zettl UK. Winkelmann A, et al. Nervenarzt. 2019 Dec;90(12):1254-1260. doi: 10.1007/s00115-019-00806-x. Nervenarzt. 2019. PMID: 31531686 Review. German.
In patients with multiple sclerosis (MS) primary varicella zoster virus (VZV) infections (chickenpox) or reactivation (shingles, herpes zoster) pose a particular challenge for neurologists and physicians in everyday clinical practice. ...
In patients with multiple sclerosis (MS) primary varicella zoster virus (VZV) infections (chickenpox) or reactiv …
Complex interaction between mutant HNRNPA1 and gE of varicella zoster virus in pathogenesis of multiple sclerosis.
Kattimani Y, Veerappa AM. Kattimani Y, et al. Autoimmunity. 2018 Jun;51(4):147-151. doi: 10.1080/08916934.2018.1482883. Epub 2018 Jul 11. Autoimmunity. 2018. PMID: 29996671 Review.
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system causing axonal injury, neuronal loss, and atrophy of the central nervous system leading to permanent neurological and clinical disability. ...Varicella zoster virus (VZV), known
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system causing axonal injury, neuronal loss, and atr
Vaccines in Multiple Sclerosis.
Williamson EM, Chahin S, Berger JR. Williamson EM, et al. Curr Neurol Neurosci Rep. 2016 Apr;16(4):36. doi: 10.1007/s11910-016-0637-6. Curr Neurol Neurosci Rep. 2016. PMID: 26922172 Review.
There are several unique considerations with respect to vaccination in the multiple sclerosis (MS) population. First, there has been concern that vaccination may trigger or aggravate the disease. ...
There are several unique considerations with respect to vaccination in the multiple sclerosis (MS) population. First, there ha …
Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis.
Manouchehrinia A, Tanasescu R, Kareem H, Jerca OP, Jabeen F, Shafei R, Breuer J, Neal K, Irving W, Constantinescu CS. Manouchehrinia A, et al. J Neurovirol. 2017 Dec;23(6):839-844. doi: 10.1007/s13365-017-0569-1. Epub 2017 Sep 11. J Neurovirol. 2017. PMID: 28895088 Free PMC article.
Varicella zoster virus (VZV) infection has been implicated in multiple sclerosis (MS), but direct causal involvement has been disputed. ...Of these, 83 reported 1 episode; 12 had 2; 5 had 3; and 1 each reported 5, 6, and 15 episodes. Of 51 patients tes
Varicella zoster virus (VZV) infection has been implicated in multiple sclerosis (MS), but direct causal involvement ha
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group. Cohen JA, et al. N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089954 Free article. Clinical Trial.
METHODS: In this 12-month, double-blind, double-dummy study, we randomly assigned 1292 patients with relapsing-remitting multiple sclerosis who had a recent history of at least one relapse to receive either oral fingolimod at a daily dose of either 1.25 or 0.5 mg or …
METHODS: In this 12-month, double-blind, double-dummy study, we randomly assigned 1292 patients with relapsing-remitting multiple
The frequency of varicella-zoster virus infection in patients with multiple sclerosis receiving fingolimod.
Aramideh Khouy R, Karampoor S, Keyvani H, Bokharaei-Salim F, Monavari SH, Taghinezhad S, Etemadifar M, Esghaei M. Aramideh Khouy R, et al. J Neuroimmunol. 2019 Mar 15;328:94-97. doi: 10.1016/j.jneuroim.2018.12.009. Epub 2018 Dec 26. J Neuroimmunol. 2019. PMID: 30610966
Multiple Sclerosis (MS) is thought to be an autoimmune disease of the central nervous system (CNS), in which the immune system becomes activated, cross the blood-brain barrier (BBB), and cause neuroinflammation and neurodegeneration. ...In healthy individuals, the r
Multiple Sclerosis (MS) is thought to be an autoimmune disease of the central nervous system (CNS), in which the immune system
Varicella-Zoster Virus in Cerebrospinal Fluid at Relapses of Multiple Sclerosis is Infective in Vitro.
Hernández-González O, Martínez-Palomo A, Sotelo J, Chávez-Munguía B, Ordoñez G, Talamás-Lara D, Pineda B, de Jesús Flores-Rivera J, Espinosa-Cantellano M. Hernández-González O, et al. Arch Med Res. 2018 Jul;49(5):350-355. doi: 10.1016/j.arcmed.2018.10.001. Epub 2018 Oct 17. Arch Med Res. 2018. PMID: 30342846
BACKGROUND: We have reported the presence of varicella-zoster virus (VZV) DNA and viral particles in the cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients during exacerbation. ...
BACKGROUND: We have reported the presence of varicella-zoster virus (VZV) DNA and viral particles in the cerebrospinal fluid (CSF) of …
Varicella-zoster virus vasculopathy in a multiple sclerosis patient on fingolimod.
Muccilli A, Nehme A, Labrie M, Girard M, Odier C, Poppe AY. Muccilli A, et al. J Neurol Sci. 2019 Aug 15;403:119-121. doi: 10.1016/j.jns.2019.06.025. Epub 2019 Jun 26. J Neurol Sci. 2019. PMID: 31276860 No abstract available.
Antigen-shift in varicella-zoster virus-specific T-cell immunity over the course of Fingolimod-treatment in relapse-remitting multiple sclerosis patients.
Matko S, Akgün K, Tonn T, Ziemssen T, Odendahl M. Matko S, et al. Mult Scler Relat Disord. 2020 Feb;38:101859. doi: 10.1016/j.msard.2019.101859. Epub 2019 Nov 16. Mult Scler Relat Disord. 2020. PMID: 31855843
BACKGROUND: Fingolimod (FTY) applied as treatment regimen of relapsing-remitting multiple sclerosis (RRMS) induces downregulation of sphingosine-1-phosphate receptors on the lymphocytes. As a result CC chemokine receptor type 7 (CCR7) expressing lymphocytes are reta …
BACKGROUND: Fingolimod (FTY) applied as treatment regimen of relapsing-remitting multiple sclerosis (RRMS) induces downregulat …
267 results
Jump to page
Feedback